AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant survival advantage for patients with folate receptor ... Read More
AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra
AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company specializing in peptide-based drug discovery. The deal ... Read More
Xilio Therapeutics accelerates cancer immunotherapy with new masked T cell engager programs and $52m AbbVie collaboration
Xilio Therapeutics, Inc., a clinical-stage biotechnology company based in Waltham, Massachusetts, has announced the development of three new masked T cell engager programs designed to ... Read More
FDA approves EMBLAVEO to combat complicated intra-abdominal infections with limited treatment options
The U.S. Food and Drug Administration (FDA) has granted approval for EMBLAVEO (aztreonam and avibactam), marking a significant milestone in the fight against complicated intra-abdominal ... Read More
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges such as the U.S. loss of exclusivity ... Read More
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics, a company at the forefront of peptide-based ... Read More
Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma
Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab A/S, alongside its development partner AbbVie, announced ... Read More
AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top
Bristol Myers Squibb's stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development ... Read More
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising ... Read More
NImmune Biopharma collaborates with BioTherapeutics on next-gen precision medicines
NImmune Biopharma has entered into a strategic partnership with BioTherapeutics, a clinical-stage biotech company based in Virginia, to accelerate the development of next-generation precision medicines ... Read More